AgomAb Therapeutics NV (AGMB)

AgomAb Therapeutics NV Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Net Income	-62.55	-46.27	-11.39
Depreciation & Amortization	0.22	0.31	0.1
Stock-Based Compensation	5.36	1.07	2.16
Other Adjustments	3.27	-1.75	-19.8
Changes in Accounts Payable	2.36	-0.23	3.69
Changes in Income Taxes Payable	-	-0	-0
Changes in Unearned Revenue	0.75	-0.4	-0.58
Changes in Other Operating Activities	-1.15	0.44	1.24
Operating Cash Flow	-51.74	-46.83	-24.59
Capital Expenditures	-0	-0.68	-
Purchases of Investments	-30	-	40
Payments for Business Acquisitions	-3	-	-
Investing Cash Flow	-33	-0.68	40
Issuance of Common Stock	-	97.06	79.87
Net Common Stock Issued (Repurchased)	-	97.06	79.87
Other Financing Activities	-0.34	-0.29	-0.55
Financing Cash Flow	-0.34	96.76	79.32
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.05	-0.2	-
Net Cash Flow	-85.08	49.26	94.73
Free Cash Flow	-51.75	-47.5	-24.59
Free Cash Flow Per Share	-95.62	-87.79	-45.45
Levered Free Cash Flow	-60.37	-46.82	-6.95
Unlevered Free Cash Flow	-57.1	-48.57	-28.36

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q